Cis-Retinoic acid

Small molecule

MMasonic Cancer Center, University of Minnesota

Cis-Retinoic acid is one of 35 small molecule programs targeting Wilms tumor. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Wilms TumorActive, not recruiting

Juvenile Myelomonocytic LeukemiaActive, not recruiting

Wilms TumorPhase 1/Phase 2

Active, not recruiting

Juvenile Myelomonocytic LeukemiaPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

23 competitors in Juvenile Myelomonocytic Leukemia

#DrugCompanyPhaseTrials

Rydapt

Cytosar

3 3

Fludara

Sanofi

Phase 2

2 4

Mekinist

Novartis

Phase 2

2 5

Cellcept

Roche

Phase 2

1 6

Atgam

Novartis

Phase 2

1 7

Neoral

Novartis

Phase 2

1 8

Novantrone

Pfizer

Phase 2

1 9

Fludara

Sanofi

Phase 2

1 10

Cytoxan

BBaxter Healthcare Corporation

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 1/2Recruiting

Wilms Tumor

NCT05384821

Clinical

Trials by Indication[1]

Juvenile Myelomonocytic Leukemia1 trial

Cytosine Arabinoside and Mitoxantrone for Patients With Juvenile Myelomonocytic Leukemia Receiving Repeat Stem Cell Transplantation

Terminated·MMasonic Cancer Center, University of Minnesota·Phase 1/2·NCT00609739·1 enrolled

Wilms tumor1 trial

Metronomic Chemotherapy in Wilms Tumor (MetroWilms-1906)

Recruiting·CCentre Oscar Lambret·Phase 1/2·NCT05384821·28 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Cis-Retinoic acid. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Cis-Retinoic acid compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Cis-Retinoic acid. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Masonic Cancer Center, University of Minnesota company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: MMasonic Cancer Center, University of Minnesota

Cis-Retinoic acid

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Juvenile Myelomonocytic Leukemia1 trial

Wilms tumor1 trial

References

Drug Info

Quick Facts

Related News